These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3113723)

  • 1. Progressive growth of immunogenic tumors: relationship between susceptibility of ascites P815 tumor cells to T-cell-mediated lysis and immune destruction in vivo.
    Fahey JR; Hines DL
    Cancer Res; 1987 Sep; 47(18):4759-65. PubMed ID: 3113723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES
    J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
    Maryanski JL; Boon T
    Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tumor-like assay conditions, lonizing radiation, and hyperthermia on immune lysis of tumor cells by cytotoxic T-lymphocytes.
    Harris JW
    Cancer Res; 1976 Aug; 36(8):2733-9. PubMed ID: 6145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic effects of antigen- and mitogen-induced T cells on various targets.
    Bevan MJ; Cohn M
    J Immunol; 1975 Feb; 114(2 Pt 1):559-65. PubMed ID: 123541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E; Baral E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrest of the cell cycle reduces susceptibility of target cells to perforin-mediated lysis.
    De Leon M; Jackson KM; Cavanaugh JR; Mbangkollo D; Verret CR
    J Cell Biochem; 1998 Jun; 69(4):425-35. PubMed ID: 9620169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
    Balk SP; Mescher MF
    J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
    Liu Y; Bi X; Xu S; Xiang J
    Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. I. Changes in reactivity with cytotoxic T lymphocytes and anti-H-2d sera.
    Celis E; Hale AH; Russell JH; Eisen HN
    J Immunol; 1979 Mar; 122(3):954-8. PubMed ID: 312828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target cell susceptibility to immune lysis and expression of MHC antigens are independent of position in the cell cycle.
    Harris DT; Sekaly RP
    J Immunol; 1984 Jul; 133(1):40-4. PubMed ID: 6427344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
    Hiserodt JC
    J Immunol; 1985 Jul; 135(1):53-62. PubMed ID: 3158707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.